INTRODUCTION
CARD9 is a central adaptor protein in innate immune signaling via C-type lectin receptors (CLRs), such as Dectin-1, Dectin-2, and Mincle (Goodridge et al., 2009; Gross et al., 2006; Ishikawa et al., 2009; Roth and Ruland, 2013; Saijo et al., 2010; Schoenen et al., 2010; Werninghaus et al., 2009) , and has more recently been reported to regulate cytokine production induced by cytosolic nucleic acid sensors RIG-I and Rad50 in mouse models (Abdullah et al., 2012; Poeck et al., 2010; Roth et al., 2014) . CLRs sense components of fungal and bacterial cell walls, linking signaling from these immune receptors to nuclear factor-kB (NF-kB) activation through a series of sequential phosphorylation events. CARD9 thereby mediates production of pro-inflammatory cytokines, including tumor necrosis factor a (TNFa), interleukin-6 (IL-6), and IL-1b, ultimately regulating the responses of T helper 1 (Th1) and Th17 cells (Drummond et al., 2011; Glocker et al., 2009; LeibundGut-Landmann et al., 2007; Marakalala et al., 2010; Robinson et al., 2009; Saijo et al., 2010; Sokol et al., 2013) .
CARD9 was recently identified as a gene associated with determining risk for inflammatory bowel disease (IBD) (Jostins et al., 2012; Rivas et al., 2011) , ankylosing spondylitis (Pointon et al., 2010) , primary sclerosing cholangitis (Janse et al., 2011) , and immunoglobulin A (IgA) nephropathy (Kiryluk et al., 2014) . Patients with early stop codons or point mutations affecting the N-terminal portion of CARD9 also show increased susceptibility to fungal infection (Drewniak et al., 2013; Gavino et al., 2014; Gazendam et al., 2014; Glocker et al., 2009; Grumach et al., 2015; Herbst et al., 2015; Jachiet et al., 2015; Lanternier et al., 2015a; Lanternier et al., 2015b; Lanternier et al., 2013; Wang et al., 2014) . Unlike most genetic risk factors for complex diseases, CARD9 alleles exist in both predisposing and protective forms for IBD. The predisposing variant, CARD9 S12N, is caused by a common coding SNP that was identified via genome-wide association studies (GWASs) and is associated with increased expression of CARD9 mRNA (Franke et al., 2010; Jostins et al., 2012; McGovern et al., 2010; Zhernakova et al., 2008) . The protective variant, CARD9 S12ND11, is caused by a rare splice variant in which exon 11 of CARD9 is deleted. This allele, identified by deep sequencing of GWAS loci, results in a protein with a C-terminal truncation and confers strong protection against disease (p < 10 À16 ) (Beaudoin et al., 2013; Rivas et al., 2011) .
The CARD9 signaling cascade is initiated after engagement of Dectin-1 by b-glucans (which results in the phosphorylation of Dectin-1 itself) or engagement of Dectin-2 or Mincle by fungal mannans (which results in phosphorylation of the ITAM-containing signaling adaptor FcRg). These phosphorylation events activate Syk kinase, which subsequently activates PKCd to phosphorylate CARD9 at T231 (Strasser et al., 2012) . Phosphorylated CARD9 recruits BCL10 and MALT1 to form a CARD9-BCL10-MALT1 (CBM) complex, which activates the canonical NF-kB pathway (Roth and Ruland, 2013) . Rubicon acts as a feedback inhibitor by displacing CARD9 from the CBM complex and thereby terminating CARD9-mediated signaling (Yang et al., 2012) . Interestingly, a recent report showed that Dectin-1-CARD9 signaling induces neutrophilic myeloid-derived suppressor cells; these cells functionally suppress T and natural killer (NK) cell responses, suggesting that the CARD9 pathway might play an important role in balancing inflammation in response to pathogenic fungi (Rieber et al., 2015) .
Aside from the kinase-dependent steps that contribute to the initiation of the CBM signalosome and Rubicon-dependent feedback inhibition, little is known regarding other mechanisms that might regulate the assembly, stability, or activity of CARD9 in this complex. CARD9 is a scaffold protein with an N-terminal domain composed of a CARD domain followed by two coiledcoil domains. However, CARD9 has no clear domain within its C terminus, and its mode of regulation is not fully defined (Hara and Saito, 2009; Roth and Ruland, 2013) .
In this study, we used disease-associated CARD9 alleles to uncover fundamental insights into the protein-protein interactions and post-translational modifications that regulate CARD9 function. We demonstrated that the C terminus of CARD9 is a critical regulatory module for CARD9 activity and identified TRIM62 as a novel interactor with the CARD9 C terminus. We showed that TRIM62 ubiquitinates CARD9 at K125 and demonstrated that a CARD9 alteration at this residue (K125R) abrogates CLR-induced CARD9-mediated cytokine production. Furthermore, Trim62 À/À mice showed reduced CLR-CARD9-dependent cytokine production and increased susceptibility to fungal infection. In parallel, we showed that the protective CARD9 D11 variant acts in a dominant-negative fashion for CLR-CARD9-dependent cytokine signaling and that TRIM62-mediated ubiquitination does not occur in this variant protein.
RESULTS
The C Terminus of CARD9 Is Essential for CARD9 Activation The association between IBD and CARD9, which has both protective and predisposing alleles, raises the need to characterize regulatory mechanisms for CARD9-dependent pathways. To this end, we employed naturally occurring CARD9 variants characterized by C-terminal truncations to investigate CARD9 regulation. We first used a human immune cDNA panel to collect a library of naturally occurring human CARD9 alleles and screened this collection for effects on CARD9-mediated cytokine production. In addition to identifying full-length CARD9 and the diseaseassociated S12N and S12ND11 alleles, we also identified several novel variants of CARD9 ( Figures 1A and S1A ) and noted that the majority of the allelic variations affected the C-terminal portion of the protein.
To definitively evaluate whether the deletion of exon 11 (D11) imparts protection from disease, we analyzed Immunochip datasets with 33,311 IBD-affected individuals and 33,938 healthy control individuals from the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) and found that individuals with the D11 splice variant are less likely to develop IBD regardless of the presence of S12N alteration ( Figure S1B ), further suggesting an important functional role for the C terminus of CARD9.
To examine how C-terminal truncation affects CARD9 function, we stimulated CARD9-dependent pathways by using either depleted zymosan, a glucan-enriched preparation that is derived from fungal cell walls and mainly activates Dectin-1 (Gross et al., 2006) , or trehalose 6,6-dimycolate (TDM), a mycobacterial cellwall component that activates two other CLRs: Mincle and macrophage C-type lectin (Miyake et al., 2013; Roth and Ruland, 2013; Werninghaus et al., 2009) . Activation by these two ligands led to CARD9-dependent production of proinflammatory cytokines, including TNFa and IL-6 ( Figure S1C ) (Gross et al., 2006; Saijo et al., 2010; Werninghaus et al., 2009 ). We therefore re-expressed human CARD9 isoforms in murine Card9 À/À bonemarrow-derived dendritic cells (BMDCs) and assessed cytokine production in response to these ligands by ELISA ( Figures 1B-1E and S1D-S1F). BMDCs expressing the predisposing variant CARD9 S12N showed greater TNFa and IL-6 production than BMDCs expressing wild-type CARD9. In contrast, CARD9 D11 and CARD9 S12ND11, as well as the C-terminally truncated CARD9 V6, showed significant impairment in TNFa and IL-6 production. This effect did not occur when cytokine production was stimulated by lipopolysaccharide (LPS), a ligand for Toll-like receptor 4 (TLR4), indicating that the impairment was specific to the CARD9 pathway ( Figures 1D and S1E ). These data suggest that the C terminus of CARD9 is required for CLR-CARD9-mediated cytokine production.
A Protective CARD9 Variant Acts in a DominantNegative Manner Pursuing our finding that CARD9 D11 demonstrates loss of CARD9 function (Figure 1 ), we next examined whether this variant would have a dominant-negative effect on CARD9 function when co-expressed with wild-type CARD9 in human cells.
To test this hypothesis, we expressed CARD9 D11 in the human monocytic cell line THP-1, as well as in primary human monocyte-derived dendritic cells (MDDCs), and found that CARD9 D11 suppressed depleted zymosan-induced NF-kB activation in THP-1 cells (Figures 2A and 2B ) and depleted zymosaninduced TNFa production in MDDCs (Figures S2A and S2B) . Consistent with these findings, we also expressed CARD9 D11 in wild-type murine BMDCs and found that CARD9 D11 inhibited TDM-induced TNFa and IL-6 production ( Figures S2C and S2D ). In contrast, LPS-induced cytokine production was unaltered under the same experimental conditions in both human MDDCs and murine BMDCs ( Figures S2E and S2F) . Collectively, the results indicate that CARD9 D11 has a dominant-negative effect in both human and mouse dendritic cells. Furthermore, FLAGtagged human CARD9 D11 co-immunoprecipitated with endogenous CARD9 in wild-type murine BMDCs ( Figure 2C ). This result demonstrates that CARD9 D11 can form a complex with endogenous full-length CARD9, suggesting that CARD9 D11 might inhibit CARD9 function via hetero-oligomerization with full-length CARD9. To pursue these findings, we developed an ELISA-based assay that detects the interaction between differentially tagged purified CARD9 proteins in vitro in a cell-free system. By using GST-and FLAG-tagged purified CARD9 constructs, we confirmed that both wild-type CARD9 and CARD9 D11 are capable of directly interacting with CARD9. Importantly, the ability of CARD9 D11 to form complexes with wild-type CARD9 was not impaired ( Figure 2D ).
TRIM62 Binds the C Terminus of CARD9
Because CARD9 functions as a scaffold protein, we next investigated whether loss of specific protein-protein interactions by C-terminally truncated proteins might underlie their effects on CARD9 function. Because the details of how the C terminus of CARD9 delivers signals from receptors to effectors are largely unknown, we sought to identify novel CARD9 binding partners that might be responsible for the loss of signal transduction in the truncated proteins. To this end, we re-expressed a tagged version of wild-type CARD9 in immortalized Card9 À/À cells (Blasi et al., 1985) and employed tandem affinity purification to purify CARD9. Using mass spectrometry, we identified TRIM62 as a top hit co-purified with CARD9 on the basis of high peptide counts and a high percentage of protein coverage. Members of the TRIM family of proteins are involved in multiple cellular processes, including innate immunity (Uchil et al., 2013; Versteeg et al., 2013) , and mutations in multiple TRIM-encoding genes are associated with human disease (Marín, 2012; McNab et al., 2011) . However, most studies of TRIM proteins have employed overexpression or knockdown approaches (Arimoto et al., 2010; Tsuchida et al., 2010; Uchil et al., 2013; Versteeg et al., 2013) , and very few studies in knockout mice or human cells have examined ligand specificity (Gack et al., 2007; Zhang et al., 2013) . We next examined whether we could detect a direct interaction between CARD9 and TRIM62. To demonstrate TRIM62 binding of CARD9, we developed an ELISA-based system that employs differentially tagged CARD9 and TRIM62. These experiments demonstrated that wild-type CARD9, but not CARD9 D11, interacted with TRIM62, as assessed by CARD9-TRIM62 ELISA. Addition of purified C-terminal domain (CTD) of CARD9 abrogated this interaction, supporting the hypothesis that TRIM62 binds the C terminus of CARD9 ( Figure S3A ). To further study the molecular interaction between CARD9 and TRIM62 and the dominant-negative effect of CARD9 D11, we developed a cell-based BRET (bioluminescence resonance energy transfer) system that enables detection of specific protein-protein interactions in the context of an intact cell. BRET has been used for characterizing disease-related genetic variants of GNAL (Fuchs et al., 2013) , as well as for investigating the function of cancer-associated PTEN alterations in a dominant-negative context (Papa et al., 2014) . Notably, a BRET assay was recently used for discovering a novel CARD9 interactor in a physiologic setting (Roth et al., 2014) . In our BRET system, nanoluciferase-tagged CARD9 (donor) can interact with Halo-tagged TRIM62 (acceptor) to generate energy measured as a BRET signal ( Figure S3B ). We first confirmed that the assay robustly detects an interaction between CARD9 and TRIM62. In agreement with our findings that the interaction is mediated by the C terminus of CARD9, we found that the interaction can be competitively disrupted by co-expression of the CARD9 C terminus (amino acids 416-536) ( Figure S3C ). To more precisely examine the dominant-negative effect of CARD9 D11, we assessed the interaction between CARD9 and TRIM62 in the presence of co-expressed CARD9 D11 or negative controls such as unrelated proteins SULT1 and LacZ ( Figure S3D ). The presence of CARD9 D11 disrupted the CARD9-TRIM62 interaction, whereas SULT1, LacZ, or vector alone showed no effect. These results demonstrate the inhibitory effect of the protective variant on the CARD9-TRIM62 interaction and support the hypothesis that hetero-oligomerization of wild-type CARD9 and CARD9 D11 might functionally inhibit signaling of wild-type CARD9. Consistent with these findings, co-immunoprecipitation studies of CARD9 and TRIM62 demonstrated that CARD9 D11, CARD9 S12ND11, and CARD9 V6 failed to bind TRIM62, whereas the CARD9 C terminus alone (amino acids 416-536) bound TRIM62 even more efficiently than full-length wild-type CARD9 ( Figure 3A) . We further confirmed these results by demonstrating that endogenous CARD9 interacted with endogenous TRIM62 in a zymosan-dependent manner in THP-1 cells ( Figure S3E ). These results demonstrate that these proteins interact endogenously in an activation-dependent manner.
Having found a biochemical interaction between TRIM62 and CARD9, we next examined their colocalization by immunofluorescence. We found that TRIM62 co-localized with wild-type CARD9 and CARD9 S12N but did not co-localize with CARD9 variants lacking the C terminus (CARD9 D11, CARD9 S12N D11, or CARD9 V6) in HeLa cells ( Figures S3F-S3H) ; all isoforms of CARD9 showed relatively diffuse cytoplasmic localization when expressed alone, whereas TRIM62 showed a diffuse localization with some cytoplasmic bodies, consistent with localization patterns observed for TRIM5a (Campbell et al., 2007) and TRIM22 (Reymond et al., 2001) (Figures S3F-S3H ). Consistent with these observations, endogenous CARD9 and TRIM62 colocalized in a zymosan-dependent manner in wild-type BMDCs ( Figures 3B and 3C) .
Furthermore, using THP-1 cells in which endogenous CARD9 had been deleted with CRISPR, we re-expressed tagged wildtype CARD9 or CARD9 D11 and found that although wild-type CARD9 colocalized with endogenous TRIM62 in a stimulationdependent manner, CARD9 D11 did not ( Figures 3D and 3E) . Notably, TRIM62 co-localized with BCL10, a well-characterized CARD9 interactor, in a zymosan-dependent manner in wild-type BMDCs, suggesting that TRIM62 might associate with CARD9 as part of the CBM complex ( Figures S3I and S3J ).
TRIM62 Induces K27-Linked CARD9 Ubiquitination
We next examined the functional consequences of the CARD9-TRIM62 interaction. TRIM family proteins generally modify their targets via E3 ligase activity, which can include ubiquitination, SUMOylation, or ISGylation (Chu and Yang, 2011; McNab et al., 2011) . We found that TRIM62 specifically promoted CARD9 ubiquitination in HEK293T cells ( Figure 4A ) and confirmed that endogenous CARD9 was ubiquitinated in a Coomassie gel on the right shows purified proteins used in the ELISA. See also Figure S2 .
stimulation-dependent manner in dendritic cells ( Figure 4B ). We next designed an E3-ligase-dead variant of TRIM62 by changing two conserved catalytic cysteines in the RING domain to alanine (TRIM62 C11A;C14A) (Deshaies and Joazeiro, 2009 ) and showed that CARD9 ubiquitination was dependent on E3 ligase activity in HEK293T cells ( Figure 4C ). Importantly, CARD9 D11 was not ubiquitinated by TRIM62 ( Figure 4D ). Similarly to wildtype TRIM62, TRIM62 C11A;C14A colocalized extensively with CARD9 ( Figure S4 ). Next, we identified which type of ubiquitin linkage was occurring on CARD9 and showed that ubiquitination was dramatically reduced by a K27R alteration in ubiquitin ( Figure 4E ). In a reciprocal assay using ubiquitin mutants that each contained only one lysine, we found that K27 alone was sufficient for TRIM62-mediated ubiquitination of CARD9 ( Figure 4F ). Alto- See also Figure S3 .
gether, we conclude that TRIM62 mediates K27-linked ubiquitination of fulllength CARD9, but not CARD9 D11.
CARD9 Ubiquitination by TRIM62 Plays a Critical Role in CLR-CARD9 Signaling
To identify the specific CARD9 lysine target or targets ubiquitinated by TRIM62, we first examined all 40 lysines in human CARD9. We identified 17 of these lysines as being absolutely conserved across 17 mammalian species and elected to individually change each of these residues to arginine. We found that alteration of K125 significantly reduced TRIM62-mediated CARD9 poly-ubiquitination in HEK293T cells ( Figure 5A ). Importantly, using in vitro ubiquitination assays with purified proteins, we verified that CARD9 was directly ubiquitinated by TRIM62 at residue K125; this ubiquitination was dependent on the ligase activity of TRIM62 and did not occur in CARD9 D11 ( Figure 5B ). To identify the functional consequence of this ubiquitination, we re-expressed this ubiquitination-deficient CARD9 in Card9 À/À BMDCs. We found that K125R abolished CARD9-mediated cytokine production upon depleted zymosan or TDM stimulation ( Figures S5A-S5D ), indicating that ubiquitination of CARD9 K125 is critical for CARD9 activation. Similar results were obtained in human CARD9 À/À THP-1 cells reconstituted with wild-type CARD9 or CARD9 K125R. In this system, we found that stimulation-dependent NF-kB activity was dramatically reduced by the introduction of K125R ( Figures 5C and 5D ). Notably, in Card9 À/À BMDCs reconstituted with wild-type CARD9 or CARD9 K125R, both the wild-type and altered forms of CARD9 retained zymosan-dependent colocalization with BCL10 ( Figures S5E and S5F) . However, the CARD9-BCL10 interaction remained unproductive in the context of K125R, as shown by the disruption of NF-kB activity by this alteration. Taken together, these results demonstrate 
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FS-CARD9 Δ11 FS-CARD9 S12NΔ11 FS-CARD9 V6 V5-TRIM62 3xMyc-Ub (E and F) HEK293T cells were transfected with indicated constructs, immunoprecipitated for tagged CARD9, and then blotted for indicated ubiquitin mutants. In (E), transfected ubiquitin constructs have single point alterations in the indicated lysine residues. In (F), transfected ubiquitin constructs have point alterations in multiple lysines, leaving only the indicated lysine residue intact. FS, FLAG-StrepII. See also Figure S4 . that K125-mediated ubiquitination is critical for CARD9-mediated NF-kB signaling.
TRIM62 Regulates Immune Responses and Susceptibility to Candida albicans Infection In Vivo
To directly assess whether the novel CARD9 interactor TRIM62 is important for immune responses elicited via the CARD9 signaling pathway, we generated Trim62 À/À mice ( Figures S6A   and S6B ). Intravenous injection of heat-killed C. albicans, a fungal pathogen that activates the CLR-CARD9 pathway, induced acute, systemic IL-6 production, which was significantly impaired in the absence of TRIM62 ( Figure 6A ). To examine pathways involved in pro-inflammatory cytokine production, we used intracellular staining and flow cytometry to measure activity of both NF-kB and mitogen-activated protein kinase (MAPK) pathways, given that a recent study in macrophages identified a role for ERK signaling in susceptibility to Candida (Jia et al., 2014) . Isolated wild-type and Trim62 À/À splenic dendritic cells were stimulated ex vivo for 10 min with LPS or heat-killed C. albicans. Consistent with the in vivo findings, Trim62 À/À dendritic cells had less phosphorylated IkBa and ERK1/2 in response to heat-killed C. albicans stimulation, indicating impaired NF-kB and MAPK signaling, respectively ( Figure S6C ). This difference was not observed in response to LPS, indicating that the impaired signaling was specific to the CLR-CARD9 signaling pathway. These results are in agreement with a recent report showing that TRIM62 knockdown in human primary macrophages did not affect MyD88-dependent signaling at early time points (Uchil et al., 2013) . In addition to observing impaired proinflammatory pathway activation and cytokine production in response to heat-killed C. albicans, we found by using live C. albicans infection that Trim62 À/À mice had significantly more C. albicans colony-forming units (CFUs) present in the kidney, spleen, and liver (Figure 6B ), suggesting impaired pathogen clearance. To determine whether the increased fungal burden in Trim62 À/À mice after in vivo infection was due to defective phagocytosis, we exposed bone-marrow-derived macrophages (BMDMs) to fluorescently labeled C. albicans and determined uptake via flow cytometry. Uptake of C. albicans was comparable in wild-type and Trim62 À/À mice, indicating that the enhanced fungal burden in Trim62 À/À mice was not due to differences in phagocytosis efficiency ( Figure 6C ). Additionally, expression of cytokines and chemokines important during C. albicans infection was significantly lower in Trim62 À/À mice than in wild-type mice, suggesting that downstream inflammatory signaling events (through the TRIM62-CARD9 pathway) are blunted ( Figure S6D ). Lastly, to determine whether the decreased cytokine responses and increased fungal burden in Trim62 À/À mice after infection confer enhanced susceptibility to C. albicans, we monitored mice over time after in vivo infection. Strikingly, and consistent with the above data, Trim62 À/À mice were more susceptible to in vivo C. albicans infection, such that they showed 100% mortality by day 15 after infection ( Figure 6D ). Given the association between this pathway and IBD, we also assessed Trim62 À/À mice in the dextran sulfate sodium (DSS) model of intestinal inflammation. As in previously published studies in Card9 À/À mice, compared to wild-type mice treated with DSS, Trim62 À/À mice showed increased weight loss, greater inflammation, and impaired cytokine responses ( Figures  S6E-S6G ). Taken together, these results demonstrate that TRIM62 is important for immunity in in vivo models of C. albicans infection and DSS-induced colitis. +  +  +  +  +  +  +  +  V5-TRIM62   WT  WT  K58R  K60R  K97R  K93R  K125R  K150R  K156R  K233R  K306R  K340R  K383R  K391R  K490R  K496R  K505R 
DISCUSSION
CARD9 coding mutations are associated with multiple immunerelated diseases, underscoring the physiologic importance of CARD9 signaling in immunity. In the current study, we used a CARD9 allele strongly protective against IBD as an entry point to uncovering basic insights into the biology of CARD9 regulation, as well as a potential mechanism for the protective effect of the D11 variant. Through systematic pathway mapping, we found a CARD9 C-terminal interacting partner that regulates CARD9 function in a ligand-specific manner; this interactor (TRIM62), which does not interact with the protective variant of CARD9, acts as an E3 ubiquitin ligase to activate CARD9 function. Given our findings that TRIM62 acts as a restriction factor for fungal infections, our results expand the list of E3 ligases that function as restriction factors and extend the range of pathogens implicated in TRIM family signaling. The TRIM family of proteins expanded relatively recently in evolution (Ozato et al., 2008) and play important roles in the crosstalk between the innate and adaptive immune systems (Rajsbaum et al., 2014a) . The majority of studies of TRIM proteins have focused on their roles as antiviral restriction factors (Ozato et al., 2008) , and recent screens have reported that mRNA and localization of most known TRIM proteins are altered during viral infection (Uchil et al., 2013; Versteeg et al., 2013) . Extending these studies, a recent report identified that TRIM5 is a regulator of autophagy and acts as a restriction factor against HIV-1 (Mandell et al., 2014) . TRIM family members largely function in negative regulatory circuits, as was recently demonstrated for TRIM9, a negative regulator of NF-kB pro-inflammatory cytokine signaling (Shi et al., 2014 ). An increasing number of TRIM proteins have also been described as enhancers of innate immune pathways, as in the case for TRIM44, which stabilizes MAVS to enhance signaling (Yang et al., 2013) . TRIM proteins mediate several types of ubiquitin linkages, and most studies focus on K48-and K63-based linkages and their respective roles in degradation and stabilization of protein complexes (Davis and Gack, 2015; Flannick et al., 2014; Gack et al., 2007; Rajsbaum et al., 2014b; Tsuchida et al., 2010; Zhao et al., 2012) , although K27-linked ubiquitination has been reported for TRIM23 (Arimoto et al., 2010) . Our findings of TRIM62-mediated K27-linked ubiquitination of CARD9 suggest that this type of linkage promotes an important mechanism for protein activation, although notably the K125R alteration does not affect colocalization of CARD9 and BCL10. To date, all clinically reported homozygous or compound-heterozygous carriers with either no CARD9 expression or CARD9 loss of function are more susceptible to fungal infection (Drewniak et al., 2013; Gavino et al., 2014; Gazendam et al., 2014; Glocker et al., 2009; Grumach et al., 2015; Herbst et al., 2015; Jachiet et al., 2015; Lanternier et al., 2015a; Lanternier et al., 2015b; Lanternier et al., 2013; Wang et al., 2014) . Our results from Trim62 À/À mice suggest that TRIM62-mediated regulation of CARD9 activation is critical in the context of fungal infection. These data complement previous studies reporting critical roles for CARD9 and PKCd during C. albicans infection and suggest that TRIM62 is a novel member of this pathway and is important for anti-fungal immunity (Gross et al., 2006; Strasser et al., 2012) . Furthermore, we found that Trim62 À/À mice, similar to Card9 À/À mice, are more susceptible to DSS colitis, underscoring the importance of this pathway in intestinal homeostasis and fortifying previous reports on the relationship between fungi and IBD (Chehoud et al., 2015; Richard et al., 2015; Romani, 2011) . Next-generation sequencing has identified both a common predisposing allele and rare protective splice variant in CARD9 (Rivas et al., 2011) . The presence of both common and rare risk variants in a single gene has now been increasingly observed in multiple studies, advancing the concept that when multiple common and rare variants are discovered, the resulting allelic series can serve to anchor a dose-response relationship between gene and disease. For example, the connection between rare genetic variants and therapeutic advances has been well demonstrated by PCSK9 in modulating amounts of low-density lipoprotein cholesterol, where protective variation can be therapeutically mimicked (Cohen et al., 2006) , and a recent finding of SLC30A8 loss-of-function mutations that protect against type 2 diabetes (Flannick et al., 2014 ). Our findings demonstrate that the protective CARD9 variant does not undergo ubiquitination by TRIM62, and we propose that the protective effect of See also Figure S6 .
the C-terminal truncation might be mediated by loss of TRIM62 interaction and thereby limit proinflammatory cytokine responses. Given that TRIM62-dependent ubiquitination and subsequent activation of CARD9 might be targetable, these findings suggest a model in which a naturally occurring protective allele might be used as a guide for rational design of therapeutics. Indeed, evolution has ''validated'' this approach as a safe and effective strategy for decreasing the likelihood of developing IBD.
EXPERIMENTAL PROCEDURES Plasmids
For lentiviral vectors, FLAG-StrepII fusion human CARD9 variants were constructed by PCR-based subcloning of CARD9 coding sequences into a lentivirus-based CSGW vector backbone (gift from Christian Mü nz, University of Zurich). For other CARD9 constructs, CARD9 was cloned into either a pCMV vector (see section ''CARD9 Variant Cloning'' in the Supplemental Experimental Procedures) or pcDNA4/TO-FLAG-StrepII. Ubiquitin cDNA was kindly provided by Dr. M. Scheffner (University of Konstanz, Germany). All other genes were originally obtained from either OpenBiosystems or Origene and subcloned into indicated tagged vectors by PCR. Wild-type and altered ubiquitin, SUMO1, SUMO2, SUMO3, and ISG15 were subcloned into pCMV-3xMyc. pCMV-3xHA and pCMV-3xMyc were derived from pCMV-Myc (Clontech). TRIM62 constructs were subcloned into either pCMV-3xHA or pcDNA4/TO-V5. pcDNA4/TO-FLAG-StrepII and pcDNA4/TO-V5 were derived from pcDNA4/TO (Invitrogen). FLAGStrepII, HA, and Myc are all N-terminal tags. All cDNAs were confirmed by DNA sequencing.
Chemical Reagents
Depleted zymosan was purchased from Invivogen. Trehalose 6,6'-dimycolate (TDM) was obtained from Enzo Life Sciences. TDM was dissolved in 1 mg/ml chloroform, methanol, and water at a 90:10:1 ratio and further diluted with isopropanol. LPS was purchased from Sigma or Invivogen.
Cell Culture and Lentiviral Production HEK293T and HeLa cells were maintained at 37 C and 5% CO 2 in DMEM supplemented with 10% fetal calf serum and 15 mg/ml gentamycin sulfate. THP-1 cells were maintained at 37 C and 5% CO 2 in RPMI1640 supplemented with 10% fetal calf serum, 5 3 10 À4 M beta-mercaptoethanol, and 15 mg/ml gentamycin sulfate. For preparing lentivirus for infection, protocols from the Broad Institute's RNAi Consortium shRNA Library were used (http://www. broadinstitute.org/rnai/trc/lib). The Lentivirus qPCR Titer Kit (Applied Biological Materials) was used for lentiviral titration. pSIV3 + plasmid for generating Vpx-VLP was a gift from Dr. Andrea Cimarelli (É cole Normale Supé rieure de Lyon, France) (Berger et al., 2011) . Preparation of Heat-Killed C. albicans C. albicans strain SC5314 (ATCC MYA-2876) was obtained from Eleftherios Mylonakis (Massachusetts General Hospital, Boston). C. albicans were harvested from an overnight culture in YPD medium (Y1375, Sigma) at 30 C. C. albicans were washed with PBS twice and resuspended in PBS at 2 3 10 8 /ml. Resuspended C. albicans were then incubated for 2 hr at 68 C and cooled on ice. Heat-killed cell death was verified by cell plating on YPD agar plates.
In Vivo Injection of Heat-Killed C. albicans 1 3 10 7 heat-killed C. albicans in PBS were injected intravenously (i.v.). After 4 hr, serum was harvested, and IL-6 amounts were determined via ELISA.
Ex Vivo Splenic DC Stimulations and Intracellular Phosphoprotein Staining CD11c + cells were positively selected from the spleen with MACS technology according to the manufacturer's (Miltenyi Biotec) protocol. 1 3 10 6 cells were resuspended in complete RPMI (10% fetal bovine serum and 15 mg/ml gentamicin) and incubated for 10 min at 37 C with 5% CO 2 in one of three conditions: (1) no stimulation, (2) 100 ng/ml LPS stimulation, or (3) 1 3 10 6 heat-killed Mice Card9 À/À mice have been previously described (Hara et al., 2007) . Mice were maintained in specific-pathogen-free facilities at Massachusetts General Hospital. All animal studies were conducted under protocols approved by the Institutional Animal Care and Use Committee (IACUC) at Massachusetts General Hospital.
Statistical Analysis
Unpaired two-tailed Student's t tests were used for comparisons for ELISA. All statistical comparisons were made between multiple independent experiments performed in parallel. 
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